Feedback / Questions
pinatuzumab vedotin (RG7593) - Roche
Roche: Late-Stage Pipeline Event
(Roche)
-
Oct 2, 2013 -
"ADCs in hematology: Anti-CD22 and anti-CD79b: Phase I responses in multiple histologies"; "Anti-tumor responses observed by histology"
P1 data
•
Hematological Malignancies • Oncology
http://www.roche.com/investors/ir_agenda/late-stage_pipeline_2013.htm
Oct 2, 2013
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.